Novartis Plans To Buy Back Speedel For $880 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
You may also be interested in...
Institutionalizing Externalization At Big Pharma – The Third Leg
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
Vitae’s Debt Financing Braves Renin Inhibitor Risk, FDA Wariness In Diabetes
Two lenders wade in despite harsh credit environment for biotechs.
Vitae’s Debt Financing Braves Renin Inhibitor Risk, FDA Wariness In Diabetes
Two lenders wade in despite harsh credit environment for biotechs.